Spectral AI (MDAI) Projected to Post Earnings on Tuesday

Key Points

• Spectral AI (MDAI) is set to release its Q2 2025 earnings on August 12th, with expectations of a loss of ($0.07) per share and revenues of $5.44 million.
• The company's stock price recently traded at $2.41, with a market capitalization of $60.89 million and a P/E ratio of -4.45.
• Wall Street Zen has upgraded Spectral AI from a "sell" rating to a "hold" rating as of May 22nd.

Spectral AI (NASDAQ:MDAI - Get Free Report) is projected to post its Q2 2025 quarterly earnings results after the market closes on Tuesday, August 12th. Analysts expect Spectral AI to post earnings of ($0.07) per share and revenue of $5.44 million for the quarter.

Spectral AI Price Performance

MDAI traded up $0.04 during trading on Friday, hitting $2.44. 245,612 shares of the stock traded hands, compared to its average volume of 500,144. The firm has a market capitalization of $61.78 million, a P/E ratio of -4.52 and a beta of 0.90. The firm has a 50-day moving average of $2.38 and a 200 day moving average of $1.82. Spectral AI has a 12-month low of $0.82 and a 12-month high of $3.25.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Spectral AI stock. Geode Capital Management LLC grew its stake in Spectral AI, Inc. (NASDAQ:MDAI - Free Report) by 21.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 152,958 shares of the company's stock after purchasing an additional 27,365 shares during the quarter. Geode Capital Management LLC owned about 0.60% of Spectral AI worth $379,000 at the end of the most recent quarter. Institutional investors and hedge funds own 67.08% of the company's stock.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded shares of Spectral AI from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd.

Spectral AI Company Profile

Spectral AI, Inc, an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers.